Mammographic assessment of breast density as a tool for predicting the response to neoadjuvant therapy in breast cancer patients.

pCR is a highly significant endpoint in HER2+ [ 14 ] and triple-negative [ 15 ] BC patients, while in luminal subtypes, its role is not so well proven [ 10 , 43 ].

also in 132,142 other papers